X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dasatinib (512) 512
humans (480) 480
index medicus (392) 392
oncology (312) 312
imatinib mesylate (193) 193
pyrimidines - pharmacology (187) 187
protein kinase inhibitors - pharmacology (178) 178
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (173) 173
chronic myelogenous leukemia (171) 171
animals (167) 167
imatinib (164) 164
chronic myeloid-leukemia (159) 159
hematology (158) 158
thiazoles - pharmacology (151) 151
pyrimidines - therapeutic use (148) 148
chronic myeloid leukemia (144) 144
bcr-abl (136) 136
hemic and lymphatic diseases (135) 135
dasatinib bms-354825 (133) 133
benzamides (131) 131
bms-354825 (130) 130
cell line, tumor (130) 130
protein kinase inhibitors - therapeutic use (130) 130
female (124) 124
research (120) 120
male (119) 119
thiazoles - therapeutic use (114) 114
antineoplastic agents - therapeutic use (108) 108
mice (104) 104
leukemia (102) 102
drug therapy (101) 101
cancer (99) 99
antineoplastic agents - pharmacology (97) 97
mutation (97) 97
nilotinib (96) 96
kinases (92) 92
tyrosine kinase inhibitor (89) 89
phosphorylation (88) 88
protein-tyrosine kinases - antagonists & inhibitors (87) 87
tyrosine kinase (86) 86
middle aged (84) 84
drug resistance, neoplasm (83) 83
adult (82) 82
src-family kinases - antagonists & inhibitors (82) 82
kinase inhibitor (80) 80
in-vitro (75) 75
piperazines - therapeutic use (75) 75
src-family kinases - metabolism (73) 73
tyrosine (72) 72
aged (70) 70
cell proliferation - drug effects (70) 70
genetic aspects (69) 69
resistance (69) 69
piperazines - pharmacology (68) 68
activation (67) 67
pyrimidines - adverse effects (67) 67
pharmacology & pharmacy (66) 66
src (66) 66
apoptosis (65) 65
dosage and administration (65) 65
article (63) 63
apoptosis - drug effects (61) 61
cytogenetic responses (61) 61
fusion proteins, bcr-abl - antagonists & inhibitors (61) 61
cell biology (60) 60
fusion proteins, bcr-abl - genetics (60) 60
tyrosine kinase inhibitors (59) 59
care and treatment (56) 56
imatinib-resistant (56) 56
thiazoles - adverse effects (56) 56
pyrimidines - administration & dosage (55) 55
chronic-phase (54) 54
health aspects (54) 54
therapy (54) 54
treatment outcome (54) 54
c-src (53) 53
leukemia, myelogenous, chronic, bcr-abl positive - genetics (52) 52
signal transduction (51) 51
expression (49) 49
protein kinase inhibitors - administration & dosage (49) 49
leukemia, myelogenous, chronic, bcr-abl positive - pathology (48) 48
proteins (48) 48
research article (48) 48
thiazoles - administration & dosage (48) 48
cml (46) 46
protein kinase inhibitors - adverse effects (46) 46
biochemistry & molecular biology (45) 45
signal transduction - drug effects (45) 45
dose-response relationship, drug (44) 44
physiological aspects (44) 44
medicine (42) 42
neoplasms (42) 42
acute lymphoblastic-leukemia (41) 41
drug resistance (41) 41
tumors (41) 41
multidisciplinary sciences (40) 40
fusion proteins, bcr-abl - metabolism (39) 39
protein-tyrosine kinase (38) 38
cells (37) 37
chemotherapy (37) 37
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (640) 640
German (2) 2
Japanese (2) 2
Korean (2) 2
Portuguese (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2006, Volume 49, Issue 23, pp. 6819 - 6832
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2005, Volume 11, Issue 19, pp. 6924 - 6932
Purpose: Epithelial tumors, including non–small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), present clinical challenges. One... 
non–small cell lung cancer | dasatinib | tyrosine kinase inhibitor | Src | BMS-354825 | head and neck squamous cell carcinoma | SURVIVAL | ACTIVATION | THERAPY | ONCOLOGY | PHOSPHORYLATION | RECEPTOR | TUMOR-CELLS | FOCAL ADHESION KINASE | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | C-SRC | Laminin - pharmacology | Paxillin - metabolism | Lung Neoplasms - drug therapy | Phosphorylation | Cell Proliferation | Immunoprecipitation | Trypan Blue - pharmacology | Humans | Neovascularization, Pathologic | Lung Neoplasms - pathology | Crk-Associated Substrate Protein - metabolism | Dose-Response Relationship, Drug | Time Factors | S Phase | src-Family Kinases - metabolism | Inhibitory Concentration 50 | Antineoplastic Agents - pharmacology | Collagen - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Dasatinib | Signal Transduction | Focal Adhesion Protein-Tyrosine Kinases - metabolism | Neoplasm Invasiveness | Retinoblastoma Protein - metabolism | Enzyme Inhibitors - pharmacology | Head and Neck Neoplasms - drug therapy | Pyrimidines - pharmacology | Blotting, Western | Head and Neck Neoplasms - pathology | G1 Phase | Cell Cycle | Proteoglycans - pharmacology | Cell Line, Tumor | Gentian Violet - pharmacology | Thiazoles - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenosine Triphosphate - chemistry | Drug Combinations | Apoptosis | Cell Movement | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Journal Article
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 06/2006, Volume 66, Issue 11, pp. 5790 - 5797
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2006, Volume 12, Issue 23, pp. 7180 - 7186
Purpose: Chronic myeloid leukemia (CML) is caused by reciprocal translocation between chromosomes 9 and 22, forming BCR-ABL, a constitutively activated... 
pharmacokinetics | imatinib resistance | Dasatinib | biomarker | BCR-ABL | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | INTERFERON | ONCOLOGY | PHILADELPHIA-CHROMOSOME | BLAST CRISIS | TYROSINE KINASE INHIBITOR | PHASE-II | IMATINIB MESYLATE | CHRONIC MYELOID-LEUKEMIA | METASTATIC BREAST | Predictive Value of Tests | Thiazoles - blood | Injections, Intravenous | Nuclear Proteins - analysis | Pyrimidines - blood | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Thiazoles - administration & dosage | Transplantation, Heterologous | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Thiazoles - pharmacokinetics | Dose-Response Relationship, Drug | Time Factors | Adaptor Proteins, Signal Transducing - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Biomarkers, Tumor - antagonists & inhibitors | Disease Models, Animal | Administration, Oral | Biomarkers, Tumor - analysis | Pyrimidines - administration & dosage | Mice, SCID | Blotting, Western | Xenograft Model Antitumor Assays | Adaptor Proteins, Signal Transducing - analysis | Animals | Fusion Proteins, bcr-abl - analysis | Nuclear Proteins - antagonists & inhibitors | Fusion Proteins, bcr-abl - antagonists & inhibitors | Antineoplastic Agents - blood | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Mice
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 04/2007, Volume 6, Issue 4, pp. 1400 - 1405
Journal Article
The Oncologist, ISSN 1083-7159, 10/2013, Volume 18, Issue 10, pp. 1091 - 1092
摘要 背景 . 胰腺导管腺癌(PDAC)中Src、EphA2和血小板衍生生长因子受体α和β水平失调。达沙替尼是一种口服的多靶点酪氨酸激酶抑制剂,靶向作用于BCR‐ABL、c‐Src、c‐KIT、血小板衍生生长因子受体β和EphA2。我们开展了一项达沙替尼一线治疗转移性PDAC患者的II期单臂研究。 方法 .... 
ONCOLOGY | Dasatinib | Adenocarcinoma - pathology | Pancreatic Neoplasms - epidemiology | Pyrimidines - administration & dosage | Humans | Pancreatic Neoplasms - pathology | Kaplan-Meier Estimate | Thiazoles - administration & dosage | Adenocarcinoma - drug therapy | Thiazoles - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Pancreatic Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Neoplasm Metastasis - drug therapy | Neoplasm Metastasis - pathology | Neoplastic Cells, Circulating | Pyrimidines - adverse effects | Adenocarcinoma - epidemiology | Clinical Trial Results
Journal Article
Journal Article
Journal Article
Clinical Immunology, ISSN 1521-6616, 2008, Volume 127, Issue 3, pp. 330 - 339
Journal Article